Live Breaking News & Updates on Currently Negotiating Similar Potential Contracts

Following the completion of the spin-off of the Upjohn Business
(4) in the fourth quarter of 2020, Pfizer now operates as a focused innovative biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, sales and distribution of biopharmaceutical products worldwide.
Revenues and expenses associated with the Upjohn Business
(4) for first-quarter 2020 have been recategorized as discontinued operations and excluded from Adjusted
(2) results. Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, which had been reported within the results of the Upjohn Business
(4) in the first three quarters of 2020
, is now included within the Hospital therapeutic area for all periods presented. ....

South Africa , South African , Frank Damelio , Mylannv Mylan , Vyndaqel Vyndamax , Albert Bourla , Eli Lilly , Us Centers For Disease , Amplyx Pharmaceuticals Inc , Arthritis Advisory Committee , Gilead Sciences Inc , Health Inc , Pfizer Inc , Risk Management Advisory Committee , Development Programs , European Union , Vaccine Development Program , Pfizer Patient Assistance Program , Research Developments , Israel Ministry Of Health Mo , Committee For Medicinal Products Human Use , Breast Cancer Research , Company Lilly , Drug Administration , European Commission , Advisory Committee On Immunization Practices ,